Aileron Therapeutics Files 8-K on Governance and Compensation Changes
Ticker: RNTX · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1420565
| Field | Detail |
|---|---|
| Company | Aileron Therapeutics Inc (RNTX) |
| Form Type | 8-K |
| Filed Date | Feb 29, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, bylaw-amendments
TL;DR
**Aileron Therapeutics just dropped an 8-K about leadership changes, compensation tweaks, and potential bylaw amendments.**
AI Summary
Aileron Therapeutics, Inc. filed an 8-K on February 28, 2024, reporting on various corporate governance matters. The filing indicates events related to the departure or election of directors and officers, changes to compensatory arrangements, amendments to articles of incorporation or bylaws, and the submission of matters to a vote of security holders. The company's business address is 738 Main Street #398, Waltham, MA.
Why It Matters
This filing signals potential shifts in Aileron Therapeutics' leadership, corporate structure, and executive compensation, which could influence future strategic direction and financial performance.
Risk Assessment
Risk Level: medium — Changes in leadership and corporate governance can introduce uncertainty, but the specific details are not fully disclosed in this summary.
Key Players & Entities
- Aileron Therapeutics, Inc. (company) — Registrant
- February 28, 2024 (date) — Date of earliest event reported
- Delaware (location) — State of Incorporation
- 738 Main Street #398 Waltham, MA (location) — Business Address
- 001-38130 (other) — Commission File Number
FAQ
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing was February 28, 2024.
What items were reported in this 8-K filing by Aileron Therapeutics, Inc.?
The 8-K reported on Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, and Financial Statements and Exhibits.
Where is Aileron Therapeutics, Inc. incorporated?
Aileron Therapeutics, Inc. is incorporated in Delaware.
What is the business address of Aileron Therapeutics, Inc.?
The business address of Aileron Therapeutics, Inc. is 738 Main Street #398, Waltham, MA.
What is the SEC file number for Aileron Therapeutics, Inc.?
The SEC file number for Aileron Therapeutics, Inc. is 001-38130.
Filing Stats: 1,979 words · 8 min read · ~7 pages · Grade level 12.2 · Accepted 2024-02-29 07:01:03
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq
Filing Documents
- d802393d8k.htm (8-K) — 59KB
- 0001193125-24-051759.txt ( ) — 183KB
- alrn-20240228.xsd (EX-101.SCH) — 3KB
- alrn-20240228_lab.xml (EX-101.LAB) — 18KB
- alrn-20240228_pre.xml (EX-101.PRE) — 11KB
- d802393d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements of the Company within the meaning of the Private Securities Litigation Reform Act of 1995, including statements with respect to the anticipated number of shares of Series X Non-Voting Convertible Preferred Stock that will convert into shares of Common Stock. We use words such as "anticipate," "believe," "estimate," "expect," "hope," "intend," "may," "plan," "predict," "project," "target," "potential," "would," "can," "could," "should," "continue," and other words and terms of similar meaning to help identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the risks and uncertainties discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities and Exchange Commission, and under the heading "Risk Factors" of the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January 25, 2024, and in subsequent filings that the Company files with the Securities and Exchange Commission. These forward-looking statements should not be relied upon as representing the Company's view as of any date subsequent to the date of this Current Report on Form 8-K, and we expressly disclaim any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Item9.01.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Amendment to the Restated Certificate of Incorporation of the Company, effective as of February 28, 2024 (incorporated herein by reference to Annex F to the Company's Definitive Proxy Statement on Schedule 14A (File No. 001-38130) filed with the Securities and Exchange Commission on January 29, 2024). 10.1 Aileron Therapeutics, Inc. 2021 Stock Incentive Plan, as amended (incorporated herein by reference to Annex E to the Company's Definitive Proxy Statement on Schedule 14A (File No. 001-38130) filed with the Securities and Exchange Commission on January 29, 2024). 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AILERON THERAPEUTICS, INC. Date: February 29, 2024 By: /s/ Manuel C. Alves-Aivado Manuel C. Alves-Aivado, M.D., Ph.D. Chief Executive Officer